Ibuprofen doesn’t increase bleeding risk after plastic surgery
March 31, 2016 – Patients are often instructed not to take ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) before or after surgery because of increased bleeding risk. But available evidence suggests that ibuprofen does not increase the risk of bleeding after plastic surgery procedures, according to a research review in the April issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
"Ibuprofen is a useful medication in the setting of surgery with multiple beneficial effects," write Drs. Brian Kelley, Jeffrey Kozlow and colleagues of the University of Michigan. They believe that ibuprofen may provide safe and effective pain control for selected plastic surgery procedures, while avoiding the higher risks and costs of some other pain medications.
Plastic Surgery Studies Report No Increase in Bleeding with Ibuprofen
The researchers performed a systematic review and meta-analysis of the research literature to identify high-quality studies comparing ibuprofen with other pain medications for patients undergoing plastic surgery-related operations. They found four studies in which 443 patients were randomly assigned to ibuprofen or other medications. All studies started ibuprofen either before or immediately after surgery, and continued for at least one week.
The procedures studied were cosmetic facial surgery, breast cancer surgery, hernia repair, and skin cancer surgery and reconstruction. All studies used the same ibuprofen dose (400 mg every four hours). Comparison treatments included acetaminophen, acetaminophen plus codeine, or the prescription-only NSAID ketorolac.
All of the study medications provided good pain control, the assembled data suggested. Only seven percent of patients assigned to ibuprofen and 11 percent assigned to comparison drugs reported dissatisfaction with their pain treatment. (The difference was not significant.)
Ibuprofen and other treatments were also similar in terms of bleeding risk. Rates of "surgically significant postoperative bleeding" were 3.5 percent with ibuprofen and 4.1 percent with other treatments (also nonsignificant).
A further analysis focused on the comparison between ibuprofen and acetaminophen plus codeine–a common postoperative pain medication that was used as a comparison treatment in three of the four studies. Again, there was no significant difference in pain control or bleeding risk.
"Bleeding is a significant concern for plastic surgeons and NSAIDs are routinely held with this in mind," Dr. Kelley and coauthors write. Even though ibuprofen is an inexpensive drug that is widely available over-the-counter (OTC), few studies have evaluated its use in plastic surgery patients.
The researchers emphasize that their study was limited to procedures where bleeding and hematomas (collections of blood) are easily detectable. They also acknowledge some other key limitations, particularly the small numbers of studies and patients included.
However, they believe that for plastic and dermatologic (skin) surgery procedures involving small areas, ibuprofen can provide good pain control without increasing bleeding risk. The findings are consistent with the fact that, in contrast to some other NSAIDs, ibuprofen has only short, temporary effect on the function of platelets–blood cells that play a key role in clotting.
Considering ibuprofen and other alternative medications is especially important given the rising concern about misuse or prescription opioid pain relievers, in addition to their high costs. Dr. Kelley and colleagues add, "OTC analgesics like ibuprofen are more cost effective given their effectiveness in pain control, well-established public tolerance, and low-risk qualities for abuse."
Click here to read "Ibuprofen May Not Increase Bleeding Risk in Plastic Surgery: A Systematic Review and Meta-Analysis."
Article: "Ibuprofen May Not Increase Bleeding Risk in Plastic Surgery: A Systematic Review and Meta-Analysis" (doi: 10.1097/PRS.0000000000002027)
Plastic and Reconstructive Surgery® is published by Wolters Kluwer.
About Plastic and Reconstructive Surgery
For more than 60 years, Plastic and Reconstructive Surgery® (http://journals.lww.com/plasreconsurg/) has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.
The American Society of Plastic Surgeons (ASPS) is the world's largest organization of board-certified plastic surgeons. Representing more than 7,000 Member Surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. ASPS comprises more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery. You can learn more and visit the American Society of Plastic Surgeons at http://www.plasticsurgery.org or http://www.facebook.com/PlasticSurgeryASPS and http://www.twitter.com/ASPS_news.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
For more information about our products and organization, visit http://www.wolterskluwerhealth.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.